Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.

Bassel Ericsoussi, MD Pulmonary and Critical Care Fellow University of Illinois at Chicago

Classification ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

N ENGL J MED 351;16 WWW.NEJM.ORG OCTOBER 14, 2004

Definition ,[object Object],[object Object]

The Pathophysiology of PAH ,[object Object],[object Object],[object Object]

[object Object],N ENGL J MED 351;16 WWW.NEJM.ORG OCTOBER 14, 2004

Natural History and Survival ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Poor Prognostic Factors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Hypoxia and PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Appetite Suppressant and PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CNS Stimulants and PAH ,[object Object],[object Object]

CTD and PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

HIV and PAH ,[object Object],[object Object],[object Object],[object Object]

HHV-8 and PAH ,[object Object],[object Object],[object Object]

Portal HTN and PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Myelodysplastic and PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Hemoglobinopathies and PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Hereditary Hemorrhagic Telangiectasia and PAH ,[object Object],[object Object],[object Object],[object Object]

Genetic Abnormalities and PAH ,[object Object],[object Object],[object Object]

Therapeutic Approaches to Pulmonary Hypertension ,[object Object],[object Object],[object Object],[object Object],[object Object]

Basic (Conventional) Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Anticoagulion in PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Simvastatin in PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Aspirin and Plavix in PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

ASA and Simvastatin in PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CCB in PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Prostacyclin Therapy in PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

IV Prostacyclin ( IV Epoprostenol) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Intravenous Prostacyclin (cont.) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Subcutaneous Prostacyclin (SQ Treprostinil) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Endothelin-receptor Blockers in PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Bosentan ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Sitaxsentan and Ambrisentan ,[object Object],[object Object],[object Object],[object Object],[object Object]

Nitric Oxide in PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Sildenafil in PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

VIP in PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SSRIs in PAH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Combination Therapy in PAH ,[object Object],[object Object],[object Object],[object Object],[object Object]

10 % Defined as NYHA functional class I or II who have normal hemodynamic values after at least one year of follow-up

References ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.

Recomendados

Recomendados

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Similar a Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.

Similar a Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy. (20)

Más de Bassel Ericsoussi, MD

Más de Bassel Ericsoussi, MD (20)

Último

Último (20)

Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.